JNJ Anssen Submits Supplemental Biologics License Application To U.S. FDA Seeking Approval Of CARVYKTI For Earlier Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma
Benzinga · 5h ago
Alkermes Raises FY23 Outlook Following Arbitration Award from Janssen Agreements
Benzinga · 8h ago
Vanguard Total Stock Market ETF Experiences Big Inflow
NASDAQ · 9h ago
Guru Fundamental Report for JNJ
NASDAQ · 12h ago
Dow Stocks Like Microsoft, Apple, Disney, and Verizon Reveal Two Sides of the Market
Motley Fool · 12h ago
Alkermes lifts outlook after arbitration payment from Johnson & Johnson
Seeking Alpha · 14h ago
Alkermes Raises FY23 Guidance With Final Award In Johnson & Johnson Unit Arbitration
NASDAQ · 14h ago
Narrow market proving a headwind for mutual funds, opportunity for hedge funds
Seeking Alpha · 15h ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sight Sciences (SGHT), Johnson & Johnson (JNJ) and Ultragenyx Pharmaceutical (RARE)
TipRanks · 16h ago
Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
NASDAQ · 1d ago
Janssen Presented Longer-Term Data for TECVAYLI Showing a Duration Response of 22 Months In Patients With Relapsed Or Refractory Multiple Myeloma
Benzinga · 1d ago
Johnson & Johnson's Abiomed Recalls Specific Impella 5.5 With Smartassist For Purge Fluid Leaks That Can Cause Pump Stop And Loss Of Support; Biomed Reports 179 Complaints, Three Injuries And No Deaths Related To Specific Impella 5.5 Recall
Benzinga · 1d ago
The Top 25 Stocks in the S&P 500
Investopedia · 1d ago
Johnson & Johnson Unit Recalls Impella Heart Pump, US FDA Designates Class 1 Recall Order
Johnson & Johnson Unit Recalls Impella Heart Pump, US FDA Designates Class 1 Recall Order
MT Newswires · 1d ago
ANALYSIS-Stelara patent deal puts J&J back on path to $57 bln 2025 revenue forecast
NASDAQ · 1d ago
Should You Pick Stryker Stock Over BAX For Better Returns?
NASDAQ · 1d ago
Morgan Stanley sees broader MedTech impact from weight loss drugs
Seeking Alpha · 2d ago
2 Dividend Kings Down 12% and 14% You'll Regret Not Buying on The Dip
Motley Fool · 2d ago
1 Ultra-Elite Dividend Stock to Buy Hand Over Fist in June
Motley Fool · 2d ago
Webull provides a variety of real-time JNJ stock news. You can receive the latest news about Johnson & Johnson through multiple platforms. This information may help you make smarter investment decisions.
About JNJ
Johnson & Johnson is a diversified healthcare products company. The Company is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer Health, Pharmaceutical and MedTech. Its primary focus is products related to human health and well-being. The Consumer Health segment includes a range of products that is focused on personal healthcare used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women’s health and wound care markets. The Pharmaceutical segment is focused on six therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Cardiovascular and Metabolism and Pulmonary Hypertension. The MedTech segment includes a range of products used in the interventional solutions, orthopaedics, surgery, and vision fields. Its geographic area includes the United States, Europe, Western Hemisphere (excluding the United States), and Africa, Asia and Pacific.